rethinkTHC Search
Menu
Study breakdown

CBD shows therapeutic potential across a wide range of neuropsychiatric disorders with few side effects

ReviewModerate evidence
The takeaway

A review found CBD has shown benefit for autism, anxiety, psychosis, neuropathic pain, epilepsy, and several neurodegenerative diseases, with common side effects limited to diarrhea and somnolence and low abuse potential.

Clinicians considering CBD for patients, researchers surveying the CBD therapeutic landscape, and patients exploring CBD options.

Low abuse potential

What the researchers found

CBD has demonstrated therapeutic benefit across multiple neuropsychiatric conditions including autism spectrum disorder, anxiety, psychosis, neuropathic pain, cancer pain, migraine, MS, Alzheimer disease, Parkinson disease, Huntington disease, hypoxic-ischemic injury, and epilepsy. CBD is generally well tolerated with low abuse potential. THC limitations may restrict some clinical applications.

Why it matters

The breadth of conditions where CBD shows promise, combined with its favorable safety profile, makes it one of the most versatile therapeutic candidates currently being investigated across neurology and psychiatry.

The numbers in context

CBD shows benefit across 12+ neuropsychiatric conditions listed. Most common adverse events: diarrhea and somnolence. Low abuse potential demonstrated. Over 100 naturally occurring cannabinoid chemicals in cannabis.

How the study worked

Updated narrative review of CBD and cannabinoid therapeutic potential, with emphasis on the distinction between psychotropic THC and non-psychotropic CBD effects across neuropsychiatric conditions.

What this study cannot tell us

Narrative review format without systematic methodology. Many of the cited benefits are based on preliminary evidence. The review covers conditions at very different evidence levels without always distinguishing them.

How to read the evidence

Rated moderate because the review covers a wide range of evidence, though the depth for individual conditions varies significantly.

When this study was published

Published in 2019.

The bigger picture

CBD sits at the intersection of neurology, psychiatry, and pain medicine. If even a fraction of its therapeutic potential is confirmed in rigorous trials, it could reshape treatment approaches across multiple medical specialties.

Questions still open

  • Which of these many potential indications will hold up in rigorous RCTs? What is the optimal dose for each condition? Can CBD be standardized and dosed reliably enough for mainstream clinical use?

Common questions

What conditions might CBD help?
The review lists potential benefits for autism, anxiety, psychosis, neuropathic and cancer pain, migraine, MS, several neurodegenerative diseases, and epilepsy. Evidence strength varies significantly by condition.
Is CBD safe?
CBD is generally well tolerated with main side effects of diarrhea and somnolence. It has demonstrated low abuse potential, distinguishing it from THC.

Read the original research

Cannabis and Neuropsychiatric Disorders: An Updated Review.

Acta neurologica Taiwanica, 28(2), 27-39

Citation

Chayasirisobhon, Sirichai. (2019). Cannabis and Neuropsychiatric Disorders: An Updated Review.. Acta neurologica Taiwanica, 28(2), 27-39.

Explore the wider topic